Perioperative Anticoagulation and Antiplatelet Management for EBUS Lung Biopsy

Patient Risk Assessment and Procedure Classification

The American College of Cardiology recommends classifying EBUS-guided lung biopsy as a moderate-to-high bleeding risk procedure due to the potential for significant pulmonary hemorrhage, particularly in patients with a substantial cardiovascular risk profile, such as those with recent NSTEMI and severe native coronary artery disease 1
Patients with a history of NSTEMI, severe native coronary artery disease, and occluded saphenous vein grafts are considered high-risk for thrombotic complications, but the risk decreases over time, with the highest-risk period being within the first 12 months after the acute event 1, 3

The American College of Cardiology recommends discontinuing clopidogrel 5-7 days before elective procedures requiring hemostasis, such as EBUS lung biopsy, to allow for adequate platelet turnover and restoration of hemostatic function 1, 3
The American Heart Association suggests that clopidogrel irreversibly inhibits platelet function, requiring 5-7 days for platelet turnover and restoration of adequate hemostatic function 4
The American College of Cardiology recommends continuing aspirin through most surgical procedures, but in patients not currently on aspirin, such as this case, initiation of aspirin monotherapy during the periprocedural period is not necessary and may increase bleeding risk 1, 3

The American College of Cardiology recommends resuming anticoagulation and antiplatelet therapy as soon as adequate hemostasis is confirmed, typically within 24 hours post-procedure, to minimize thrombotic risk while avoiding excessive bleeding risk 1, 2
Assessment for bleeding complications, such as hemoptysis, declining hemoglobin, and hemodynamic instability, is crucial before resuming anticoagulation and antiplatelet therapy 2

The American College of Cardiology advises against bridging with heparin or low molecular weight heparin during the apixaban interruption period, as it increases bleeding risk without proven benefit 1, 3
The American Heart Association recommends against performing procedures if clopidogrel has been held for less than 5 days, unless clinical urgency outweighs bleeding risk, to ensure adequate hemostasis and minimize thrombotic complications 1, 3